Unmet Need Cardiovascular Therapeutics Market

How big is Unmet Need Cardiovascular Therapeutics Market in 2026?

USD 1,331.8 million in 2026. The market reaches USD 3,181.9 million by 2036 at a 9.1% CAGR.

Sales of unmet need cardiovascular therapeutics are projected to expand at 9.1% CAGR from 2026 to 2036. Demand is expected to come from advanced treatments for heart failure and resistant hypertension. The scope extends to atherosclerotic cardiovascular disease, cardiomyopathies and atrial fibrillation. For the Gene Therapy segment, FDA issued a June 2026 draft guidance to help cell and gene therapy development. The update reinforces the need for clearer evidence plans as cardiovascular programs move from trial settings into clinical use.

Heart failure sets the clearest commercial reference because hospitals already track admissions and symptoms. They track safety signals and treatment response during care review. The American Heart Association reported in 2026 that about 6.7 million adults in the United States have heart failure. Japan records the fastest growth in the disclosed country set at 10.0% CAGR. Commercial value improves when evidence explains which patients receive therapy and how follow-up is managed after treatment.

Key Takeaways of Unmet Need Cardiovascular Therapeutics Market

• The unmet need cardiovascular therapeutics market is expanding as hospitals and specialty centres seek disease-modifying treatments for high-risk patients where standard care delivers inadequate long-term outcomes, with commercial adoption tied to clear patient selection criteria, referral pathways, and post-treatment monitoring responsibilities.
• By indication, Heart Failure is projected to hold 32.6% share in 2026 on measurable clinical burden and repeat hospitalisation gaps; by therapy type, Gene Therapy is estimated at 44.4% share in 2026 as disease-modification potential in rare and genetic cardiovascular conditions attracts sustained development investment.
• Japan leads growth at 10.0% CAGR through 2036, followed by the UK at 9.7% and the USA at 9.1%, each supported by specialist cardiovascular infrastructure, outcome-focused reimbursement, and established referral networks.
• High-Risk patients are forecast at 47.8% share in 2026, as concentrated poor outcomes and repeat hospital use create the clearest value case for advanced therapy developers and payer reimbursement evaluation.
• Novartis, AstraZeneca, Amgen, and Pfizer anchor competition through broad cardiovascular portfolios, while Tenaya Therapeutics, BridgeBio Pharma, Alnylam, and Cardurion advance gene therapy and RNA-based pipeline assets.
• Long-term safety monitoring, reimbursement strategy, and robust clinical evidence in defined patient populations remain the primary commercial gatekeepers, reinforced by FDA draft guidance issued in September 2025 on post-approval requirements for cell and gene therapy products.

Analyst Perspective

"The unmet need cardiovascular therapeutics market is increasingly shaped by the ability to demonstrate meaningful outcomes in patient populations where existing treatment options remain insufficient. Clinical adoption will depend on durable efficacy, long-term safety, clear patient selection, and integration with established cardiovascular pathways. Companies that strengthen clinical evidence, reimbursement readiness, and specialist referral networks will be better positioned to expand treatment access."

— Anurag Sharma, Principal Analyst at Future Market Insights

Source: FMI's proprietary forecasting model and primary research

How is the Unmet Need Cardiovascular Therapeutics Market segmented?

The Unmet Need Cardiovascular Therapeutics Market is assessed by indication and therapy type. The report covers patient population, stage and region.

The segmentation framework separates the clinical condition from the treatment approach and the patient group being treated. Indication analysis covers heart failure and resistant hypertension. The scope includes atherosclerotic cardiovascular disease, cardiomyopathies and atrial fibrillation. Therapy Type covers gene therapy and RNA therapeutics. It includes novel small molecules, biologics and precision medicines. Patient Population separates high-risk and refractory groups from rare cardiovascular conditions. This keeps adoption reasoning tied to clinical need. Stage analysis compares late-stage pipeline assets with emerging therapies. Regional analysis shows how specialist capacity and reimbursement systems change adoption across countries.

What supports demand for heart failure within the indication category?

Heart failure is a practical test for unmet cardiovascular therapeutics because clinical teams already track admissions and symptoms. They review safety signals and medication response during follow-up. Disease-modifying treatment attracts attention when standard care leaves patients with repeat deterioration. The segment benefits from measurable endpoints that make evidence easier to compare across therapy programs.

• Heart Failure is expected to hold 32.6% share in 2026, driven by persistent gaps in long-term control for advanced and high-risk patients. Adoption depends on evidence that identifies the right patient before therapy and proves durable benefit after treatment.
• Cardiology centers favor therapies that reduce uncertainty around worsening symptoms and repeat hospital use. Commercial uptake improves when a company supports referral criteria and monitoring schedules. Patient follow-up needs a defined owner.

How does gene therapy shape demand within the therapy type category?

Gene therapy is positioned around disease modification instead of repeated symptom management. FDA published draft guidance in September 2025 on postapproval methods for cell and gene therapy products. That guidance points to long-term safety and effectiveness records after approval. Cardiovascular programs therefore require strong follow-up plans before hospitals expand use.

• Gene Therapy is projected to account for 44.4% share in 2026, supported by its role in rare and genetic cardiovascular conditions. The category gains attention when treatment aims to change the disease pathway.
• Companies developing cardiovascular gene therapies need to show how treatment fits cardiac imaging and catheter-based delivery. They need clear immunosuppression rules and safety monitoring. Hospitals adopt more confidently when these steps are clear before launch.

Why does high-risk lead the patient population category?

High-risk patients form the clearest patient group because they concentrate poor outcomes and repeat hospital use. These patients give therapy developers a defined pathway for referral and monitoring. Evidence review becomes clearer when eligibility rules are narrow. Payers are expected to focus on this group when therapy cost is high and the eligible population needs careful control.

• High-Risk patients are anticipated to hold 47.8% share in 2026 as clinical teams prioritize severe disease and poor response. Higher recurrence risk gives companies a clearer value case than broad patient targeting.
• Hospitals evaluate high-risk therapy programs through eligibility rules and safety monitoring burden. Evidence becomes more useful when it shows which patient group is most likely to benefit.

How is late-stage pipeline positioned within the stage category?

Late-stage pipeline assets give the market a clearer commercial boundary than early discovery programs. Public trial records help hospitals and investors track patient groups and endpoints. Treatment settings remain important because payer discussions depend on clinical outcomes and launch readiness.

• Late-Stage Pipeline is estimated to represent 55.8% share in 2026, reflecting demand for therapies with a clearer evidence path. These programs offer better visibility on safety review and specialist-center adoption.
• Earlier therapies still shape long-term opportunity yet late-stage assets draw more commercial attention. Decision makers need evidence that explains outcomes and treatment workflow. Post-treatment responsibility has to be clear before wider adoption.

What are the drivers, restraints, and opportunities in the Unmet Need Cardiovascular Therapeutics Market?

Demand for advanced cardiovascular therapies is increasing as healthcare providers seek effective treatments for high-risk patients while balancing long-term safety and clinical evidence requirements.

• Driver: Cardiovascular specialists require therapies that reduce uncertainty in high-risk and poorly controlled patient groups.
• Restraint: Adoption slows when safety monitoring and reimbursement fit remain unclear.
• Opportunity: Governed launch pathways improve confidence for advanced therapies in defined cardiovascular patient groups.

The main driver is the need for treatments that improve decisions before costly cardiovascular deterioration. A therapy becomes easier to justify when it improves outcomes in a named patient group and does not add unclear work for specialists.

The main restraint is the gap between scientific promise and routine cardiology use. Advanced therapies often require specialized delivery and longer safety follow-up. For the Gene Therapy segment, FDA guidance on postapproval data collection shows why safety and effectiveness records matter after launch. Adoption slows when hospitals receive extra clinical work without clear payment or staffing. Monitoring support has to be defined before wider use.

The main opportunity is a governed therapy pathway. Companies that combine clinical evidence and site training create a stronger case for specialty centers and payers. Patient identification and follow-up support add practical value. FDA issued June 2026 draft guidance to help accelerate cell and gene therapies for patients. That policy direction is expected to favor programs with clear evidence plans and practical treatment steps.

Which country CAGRs are profiled in the Unmet Need Cardiovascular Therapeutics Market?

Country	CAGR
Japan	10.0%
UK	9.7%
USA	9.1%
Germany	7.9%
South Korea	7.7%

How do country-level CAGRs compare in the Unmet Need Cardiovascular Therapeutics Market?

The global CAGR reflects the combined performance of all countries included in the assessment and represents a weighted average rather than the performance of any single market. The countries presented here illustrate only part of the global landscape, indicating that additional markets outside this comparison also contribute to the overall growth profile.

• The five countries are differentiated less by the size of their CAGRs, which remain within a 2.3 percentage point range, and more by the healthcare systems and commercial pathways supporting advanced cardiovascular therapies.
• Japan and the UK form a closely positioned upper group where structured clinical pathways and evidence-based reimbursement support adoption. The USA occupies a separate middle position as commercialization depends on specialist treatment centers together with payer evaluation. Germany and South Korea remain closely aligned, although Germany emphasizes reimbursement documentation while South Korea relies more on specialist validation and digital healthcare integration.
• Markets with comparable CAGRs can therefore present different commercial conditions because regulatory review, reimbursement requirements, and clinical evidence expectations vary across healthcare systems. These differences become important when evaluating market entry and commercialization priorities across the countries assessed.

The full report examines these dynamics for every market included in the study. It provides country-level CAGR analysis across North America, Latin America, Europe, East Asia, South Asia, Oceania, and the Middle East and Africa.

Country-wise Analysis

• Japan maintains a structured cardiovascular care system where specialist referral pathways and long-term patient monitoring play a central role in treatment decisions. The country is forecast to record 10.0% CAGR from 2026 to 2036 as advanced therapies gain acceptance within disciplined clinical workflows. The Ministry of Health, Labour and Welfare updated indicators for the second national plan for cerebrovascular and cardiovascular disease measures in April 2026. The policy framework reinforces pathway improvement and specialist follow-up across cardiovascular care. Therapy developers should provide clear long-term safety evidence because clinicians place significant emphasis on monitoring after treatment.
• The UK operates through a publicly funded healthcare system where reimbursement decisions depend on demonstrated clinical value and service efficiency. Adoption is projected to expand at 9.7% CAGR through 2036 as evidence-based cardiovascular therapies progress toward wider clinical use. GOV.UK reported in December 2025 that around 1.9 million people in England had a GP diagnosis of coronary heart disease during the financial year ending March 2025. Commercial success depends on proving that advanced therapies improve patient outcomes without placing additional pressure on specialist services.
• The USA combines a large cardiovascular patient population with extensive specialist treatment networks across academic and commercial healthcare providers. The market is estimated to post 9.1% CAGR over the forecast period as hospitals evaluate advanced therapies through payer review and clinical evidence. Adoption depends on treatment-site readiness together with clearly defined post-treatment monitoring responsibilities. Companies entering the market should demonstrate which patient groups benefit most before broader commercialization.
• Germany emphasizes structured reimbursement processes and evidence-based clinical adoption across specialist cardiovascular centers. Growth is anticipated at 7.9% CAGR through 2036 as hospitals continue evaluating innovative therapies against established treatment standards. Market participants need comprehensive clinical documentation because reimbursement alignment remains essential before wider adoption.
• South Korea continues strengthening long-term cardiovascular disease management through specialist care and expanding digital healthcare infrastructure. The market is predicted to advance at 7.7% CAGR during the forecast period as healthcare providers integrate innovative therapies into established clinical pathways. Companies should align commercial strategies with specialist validation and reimbursement review before expanding patient access.

Who are the notable companies in the Unmet Need Cardiovascular Therapeutics Market?

Novartis AG, AstraZeneca plc, Amgen Inc., Pfizer Inc., Tenaya Therapeutics, Cardurion Pharmaceuticals, BridgeBio Pharma and Alnylam Pharmaceuticals are the notable companies shaping this market.

The competitive outlook combines large cardiovascular medicine companies with specialist RNA and gene therapy developers. The group includes companies focused on cardiomyopathy treatment. Larger companies compete through established cardiovascular portfolios and late-stage development capacity. Specialist developers compete through direct relevance to genetic heart disease and ATTR-CM. Commercial success depends on evidence in defined patient groups instead of corporate scale alone.

• Novartis AG and AstraZeneca plc bring broad cardiovascular or cardiometabolic reach. Amgen Inc. and Pfizer Inc. add further portfolio depth. Their advantage comes from established clinical relationships and payer familiarity.
• Tenaya Therapeutics, Inc. and Cardurion Pharmaceuticals, Inc. provide focused pipeline exposure. Their relevance is stronger where the market definition centers on disease-modifying therapy and unmet heart failure needs.
• BridgeBio Pharma, Inc. and Alnylam Pharmaceuticals, Inc. strengthen the ATTR-CM and RNA therapeutics angle. Their developments show how disease-mechanism evidence is shaping treatment decisions in cardiomyopathy.

Competitive Benchmarking: Unmet Need Cardiovascular Therapeutics Market

Company	Clinical Alignment	Therapy Fit	Evidence Basis	Geographic Reach
Novartis AG	High	Cardiovascular portfolio and heart failure evidence	Official ESC 2025 cardiovascular data announcement	Global
AstraZeneca plc	Medium	Cardiovascular and renal portfolio reach with metabolic exposure	Official therapy-area and pipeline materials	Global
Amgen Inc.	Medium	ASCVD and RNA therapeutics relevance	Official 2025 olpasiran Phase 3 update	Global
Pfizer Inc.	Medium	ATTR-CM therapy relevance	Official VYNDAMAX and ATTR-CM materials	Global
Tenaya Therapeutics, Inc.	High	Cardiovascular gene therapy programs	Official 2025 DSMB and trial updates	USA-centered clinical-stage reach
Cardurion Pharmaceuticals, Inc.	High	Heart failure pipeline programs	Official 2025 CRD-750 enrollment update	USA and global trial activity
BridgeBio Pharma, Inc.	High	ATTR-CM and cardiomyopathy treatment relevance	Official 2025 acoramidis approval and outcome updates	USA and Europe
Alnylam Pharmaceuticals, Inc.	High	RNA therapeutics and ATTR-CM relevance	Official 2025 AMVUTTRA cardiovascular approval	Global

Key Developments in the Unmet Need Cardiovascular Therapeutics Market

• In August 2025, Novartis announced plans to present 19 abstracts across its cardiovascular portfolio at the 2025 European Society of Cardiology Congress. The company highlighted Entresto data in heart failure with reduced ejection fraction due to chronic Chagas disease. The update supports Novartis relevance in cardiovascular evidence generation.
• In March 2025, Alnylam announced FDA approval of AMVUTTRA for adults with ATTR-CM. The label covers reduction of cardiovascular mortality and cardiovascular hospitalizations. It covers urgent heart failure visits. This strengthens the RNA therapeutics angle within unmet cardiovascular care.
• In February 2025, BridgeBio announced European Commission approval of BEYONTTRA for ATTR-CM. The approval was based on the pivotal ATTRibute-CM Phase 3 study. The development reinforces the role of cardiovascular outcomes in cardiomyopathy market access decisions.

Key Companies in the Unmet Need Cardiovascular Therapeutics Market

Established Cardiovascular and Cardiometabolic Companies

• Novartis AG
• AstraZeneca plc
• Amgen Inc.
• Pfizer Inc.

Specialist Cardiovascular Therapy Developers

• Tenaya Therapeutics, Inc.
• Cardurion Pharmaceuticals, Inc.
• BridgeBio Pharma, Inc.
• Alnylam Pharmaceuticals, Inc.

Unmet Need Cardiovascular Therapeutics Market - Report Scope

Coverage field	Report scope
Market breakdown	Indication, therapy type, Patient population, stage and region.
Quantitative Units	Revenue in USD Million, CAGR in %.
Market Definition	Therapies and support models aimed at cardiovascular patient groups where standard care leaves a clear treatment gap.
Regions Covered	North America and Latin America. Europe and East Asia. South Asia, Oceania and Middle East and Africa.
Countries Covered	USA and UK. Germany, Japan and South Korea.
Key Companies Profiled	Novartis AG and AstraZeneca plc. Amgen Inc. and Pfizer Inc. Tenaya Therapeutics and Cardurion Pharmaceuticals. BridgeBio Pharma and Alnylam Pharmaceuticals.
Forecast Period	2026 to 2036.

Unmet Need Cardiovascular Therapeutics Market - Research Methodology

Method	Approach
Primary Research	FMI analysts gathered input from manufacturers, service providers, technology developers, distributors, end users, procurement teams, and subject-matter experts. Interviews examined purchasing decisions, product or service evaluation, adoption barriers, approval requirements, pricing considerations, and expectations for technical or commercial support. Respondents were also asked what evidence is required before a trial, pilot, or initial order develops into regular purchasing.
Desk Research	Desk research covered government statistics, regulatory publications, trade data, industry associations, technical literature, standards, company filings, product information, and official corporate announcements. Sources were reviewed for relevance, publication date, geographic coverage, and consistency with the defined market scope. Claims relating to performance, applications, approvals, capacity, investment, and commercial activity were retained only when supported by credible public evidence.
Market Sizing and Forecasting	The market model combined the baseline value with historical performance, segment structure, pricing and volume indicators, adoption levels, company participation, and country-level demand conditions. Forecast assumptions considered economic activity, investment trends, regulatory developments, technology adoption, purchasing cycles, supply availability, and barriers to wider market use. Segment and regional estimates were reconciled before the final market total was calculated.
Data Validation	Estimates were checked against multiple independent indicators, including public data, company activity, trade patterns, industry developments, and findings from primary interviews. Validation also tested whether products, services, applications, and company revenues fell within the defined market boundaries. Adjacent categories, unsupported claims, overlapping revenues, and activities without direct market relevance were excluded to reduce double counting and maintain consistency across segments and countries.

Unmet Need Cardiovascular Therapeutics Market by Segments

Unmet Need Cardiovascular Therapeutics Market segmented by Indication:

• Heart Failure
• Resistant Hypertension
• Atherosclerotic Cardiovascular Disease
• Cardiomyopathies
• Atrial Fibrillation

Unmet Need Cardiovascular Therapeutics Market segmented by Therapy Type:

• Gene Therapy
• RNA Therapeutics
• Novel Small Molecules
• Biologics
• Precision Medicines

Unmet Need Cardiovascular Therapeutics Market segmented by Patient Population:

• High-Risk
• Refractory
• Rare Cardiovascular Conditions

Unmet Need Cardiovascular Therapeutics Market segmented by Stage:

• Late-Stage Pipeline
• Emerging Therapies

Unmet Need Cardiovascular Therapeutics Market by Region:

• North America
  • United States
  • Canada
• Latin America
  • Brazil
  • Mexico
  • Argentina
  • Chile
• Western Europe
  • Germany
  • France
  • United Kingdom
  • Italy
  • Spain
  • Benelux
  • Nordics
• Eastern Europe
  • Poland
  • Czech Republic
  • Romania
  • Hungary
• East Asia
  • China
  • Japan
  • South Korea
• South Asia and Pacific
  • India
  • ASEAN
  • Australia and New Zealand
• Middle East and Africa
  • GCC Countries
  • South Africa
  • Türkiye
  • Israel

Research Sources and Bibliography

• USA Food and Drug Administration. (2026, June 2). FDA issues draft guidance to help accelerate cell and gene therapies for patients. USA Food and Drug Administration.
• USA Food and Drug Administration. (2025, September). Postapproval methods to capture safety and efficacy data for cell and gene therapy products: Draft guidance for industry. USA Food and Drug Administration.
• GOV.UK. (2025, December). Cardiovascular disease profiles: December 2025 update. GOV.UK.
• American Heart Association. (2026, January 21). 2026 heart disease and stroke statistics. American Heart Association.
• Novartis AG. (2025, August 18). New Novartis ESC data highlights strength of cardiovascular portfolio. Novartis AG.
• Tenaya Therapeutics, Inc. (2025, July 30). Tenaya receives positive safety reviews from independent DSMBs to advance both TN-201 and TN-401 gene therapy clinical trials as designed.
• Cardurion Pharmaceuticals, Inc. (2025, August 6). Cardurion Pharmaceuticals completes enrollment in Phase 2 CYCLE trials evaluating CRD-750 in heart failure.
• Alnylam Pharmaceuticals, Inc. (2025, March 20). Alnylam announces FDA approval of AMVUTTRA® for ATTR amyloidosis with cardiomyopathy.
• European Medicines Agency. (2025, February 10). Beyonttra.

This bibliography is provided for reader reference and is not exhaustive. The full report contains the complete reference list and detailed citations.

This Report Answers

• How large is the unmet need cardiovascular therapeutics market in 2026 and 2036?
• Why does Heart Failure hold the leading Indication share in 2026?
• How does Gene Therapy influence therapy-type demand?
• Why are High-Risk patients central to adoption?
• How do country growth rates compare across USA and UK with Germany, Japan and South Korea?
• Which companies shape the unmet need cardiovascular therapeutics market?
• What limits advanced cardiovascular therapy adoption?
• How does late-stage pipeline progress affect commercial confidence?
• Which evidence points matter most before market entry?